Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, has been approved by the FDA and is expected to be launched in the United States in the second quarter of 2019. In clinical trials of Rocklatan™ the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan™ including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. Aerie is headquartered in Durham, NC.
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.
Johnson & Johnson Vision
Johnson & Johnson Vision is committed to improving and restoring sight for patients worldwide. Through their world-leading ACUVUE® Brand Contact Lenses portfolio, newly acquired cataract surgery, laser refractive surgery (LASIK) and consumer eye health businesses, they now serve more than 60 million patients a day across 103 countries. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 8,400 employees worldwide.
Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.
Carl Zeiss Meditec
Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has collaboration agreements with Regeneron Pharmaceuticalsand Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world. The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases.
To learn more, visit https://www.gene.com/
IVERIC bio is a biotechnology company with a focus on the discovery and development of novel gene therapy solutions to treat orphan inherited retinal diseases with unmet medical needs.
OPT-302 is a first-in-class VEGF-C/D inhibitor for nAMD and DME. VEGF-C/D promote angiogenesis and leakage and may contribute to sub-responsiveness to VEGF-A inhibitors. Opthea has completed a randomised, double-masked clinical trial of 2.0 mg or 0.5 mg OPT-302 in combination with 0.5 mg ranibizumab vs ranibizumab + sham. OPT-302 (2.0 mg) plus ranibizumab therapy met the primary endpoint of superiority in mean BCVA gain at 24 weeks compared to ranibizumab monotherapy in treatment-naïve patients with nAMD. The 2 mg OPT-302 group gained +14.2 letters, 0.5 mg group +9.4 letters, and control group +10.8 letters (p=0.0107). Secondary endpoints of the trial were supportive of the primary outcome. OPT-302 is also being investigated in a Phase 2a trial in patients with central-involved DME despite prior anti-VEGF-A therapy.
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Headquartered in Leuven, Belgium, Oxurion is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company.
Piper Jaffray (NYSE: PJC) is a leading investment bank focused on mergers and acquisitions, public offerings, public finance, institutional brokerage, investment management and research. Founded in 1895, the firm is headquartered in Minneapolis with offices across the U.S. and in London, Aberdeen, Zurich and Hong Kong.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
Noveome is a clinical-stage pharmaceutical company focused on development and commercialization of first-in-class therapies for challenging eye diseases. Its product, ST266, is a novel secretome obtained from amnion epithelial cells cultured under proprietary conditions. ST266 contains hundreds of biological factors at physiological concentrations and has been shown to protect and resuscitate neural and retinal ganglion cells in preclinical models. Noveome intends to employ an innovative targeted intranasal system to deliver ST266 to treat optic nerve diseases such as glaucoma and optic neuritis. Noveome has raised over $168 million and is currently funded through 2020. Eight clinical trials for eye and other indications have treated 233 subjects with no serious adverse events related to the drug and two Phase 2 studies have demonstrated anti-inflammatory efficacy.
Vertical Pharmaceuticals LLC is a division of Osmotica Pharmaceuticals plc, a fully-integrated biopharmaceutical company with corporate offices in Bridgewater, New Jersey focused on developing, manufacturing and commercializing specialty products. Our diversified product portfolio, forms the foundation of our unwavering commitment to improving patients' lives, while our late-stage pipeline is highlighted by two NDA candidates that recently completed Phase III clinical trials: arbaclofen extended‑release tablets for spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid. RVL-1201 represents our entry into eye care, and a meaningful advance in the treatment paradigm for eye-care professionals and patients alike.
AcuFocus, Inc., is a privately held ophthalmic medical device company that develops and markets breakthrough technologies for the improvement of vision. Our proven, proprietary technology platform uses a small aperture - or pinhole - effect to allow focused light rays to reach the retina and bring objects into focus. The result is unique, reliable and long-term. Designed specifically for patients with cataracts, the IC-8 IOL combines small aperture optics with the reliability of a monofocal IOL to provide an uninterrupted extended depth of focus. The lens received its CE mark in 2014 and is available in select markets across Europe and Asia. The IC-8 IOL is not currently approved in the United States. Founded in 2001, AcuFocus is based in Irvine, Calif. For additional information about the IC-8 intraocular lens, visit www.acufocus.com.
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases.
Our lead product candidate, AKB-9778, is a Tie2 activator being developed for the treatment of primary open-angle glaucoma. A topical ocular dose form is in a multiple-ascending dose Phase 1b clinical trial.
Aerpio is also developing bi-specific antibodies that activate the Tie2 pathway by inhibiting VE-PTP and inhibiting VEGF.
Aldeyra Therapeutics is a late-stage biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated ocular and systemic diseases. The company’s lead product candidate, reproxalap, is a novel Reactive Aldehyde Species (RASP) inhibitor shown to reduce ocular inflammation in dry eye disease (DED) and allergic conjunctivitis (AC). Reproxalap demonstrated statistically significant and clinically relevant activity in two Phase 2 trials in both DED and AC. Based on these results, Aldeyra believes reproxalap has the potential to offer greater efficacy than existing DED medications, particularly relative to its early onset of action and breadth of activity. The company is advancing into Phase 3 clinical development of ADX-2191, an intravitreal Dihydrofolate Reductase (DHFR) inhibitor for the prevention of proliferative vitreoretinopathy.
Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate®), Allegro’s lead investigational anti-integrin compound in retina, simultaneously acts on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as diabetic macular edema (DME) and intermediate dry age-related macular degeneration (intermediate dry AMD). Risuteganib successfully completed two Phase 2 DME studies and is currently being evaluated in a US Phase 2 intermediate dry AMD study. Allegro is preparing to expand its anti-integrin portfolio into new ocular therapeutic areas.
Millions of patients suffer from ocular surface diseases. The therapeutic benefits of autologous serum tears have been shown in more than 120 publications, but it’s use has been limited because of the inconvenience of producing the serum from individual patient blood draws. Allotears proprietary (patent pending) processing, using allogenic serum, overcomes the limitation of today’s autologous serum tears. The high degree of consistency provided by strict quality control of the critical components along with improved convenience for patients and ophthalmic professionals provides Allotears with the opportunity to transform the use blood serum tears into a mass market application.
Allysta is developing a novel peptide therapeutic, ALY688 for dry eye disease. As an analogue of a natural protein called adiponectin, it has many of the same benefits that have been seen with the natural protein, including broad anti-inflammatory effects (inhibition of proinflammatory cytokines and white cells) and accelerated repair and regeneration of epithelial cells (cornea) following injury. A clinical study of ALY688 in subjects with moderate to severe dry eye is expected to be initiated in Q4, 2019.
Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 in primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit www.aurabiosciences.com.
Avellino Labs, a world leader in genetic diagnostics and gene therapy research, with a core specialty in ophthalmology, was founded in 2008. Avellino Labs operates globally and has received multiple awards, including being named Technology Pioneer by the World Economic Forum. Avellino’s commitment to ophthalmology began with developing the first commercially available genetic test for corneal dystrophy, providing a fast and accurate test to help guide physicians and inform treatment decisions based on their patient's unique genetic code. Avellino continues to innovate and is developing next-generation sequencing based diagnostics for a number of other genetic eye diseases, including keratoconus. Avellino partnered with Ulster University to develop state-of-the-art CRISPR gene editing for corneal dystrophies providing exciting world-first treatment options.
We are working to create a bridge between promising genetic research and actual medicines with the people, platform, and processes needed to advance multiple individual therapies simultaneously. Our decentralized subsidiary model lets us distribute shared central resources while remaining hyper-focused on developing therapies for each disease. A confluence of breakthroughs in genome sequencing, molecular biology, and patient information databases and registries give us the opportunity to make therapeutic leaps against genetic disease. BridgeBio finds great science where the mechanism of a disease is well-understood and develops medicines that target those diseases at their source. BridgeBio has more than 15 drug programs for 20 genetic diseases. Ophthalmology is a key area of our interest.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. Based in Seattle, the company is innovating the next generation of cornea care, from new medical devices and biologics to cell therapy and interventions. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including delivery of the highest quality tissue with the most advanced processing techniques, surgeon training and education, advocacy and surgeon billing assistance for corneal tissue reimbursement, and investment in innovation to drive overall advancement of cornea care.
Eyenovia is a late-stage ophthalmic biopharmaceutical company with a lead program for the prevention of myopia (nearsightedness) progression. Progressive myopia is a serious, site-threatening condition that may impact up to 5 million children in the United States, with similar numbers for Europe and many more in Asia. Through the use of our transformative ophthalmic delivery platform, Eyenovia is preparing a single, de-risked Phase 3 study of MicroPineTM that may lead to the first FDA-approved treatment for this condition.
Eyenovia makes new therapies possible. Our unique delivery platform uses breakthrough piezo-print technology for high-precision micro-dosing. Micro-dosing allows for fully effective therapies that may also avoid many tolerability and side-effect issues associated with traditional eye drop delivery.
Development and commercialization of NIBS devices. First application is Eyetronic, the only CE approved non-invasive optic nerve stimulation therapy for indications related to loss of visual field caused by neuropathies of the optic nerve, such as glaucoma.
Eyevance is focused on developing and commercializing innovative and impactful ophthalmic products to enable optimal vision and better quality of life for all patients and their ophthalmic healthcare providers.
Eyevensys is a clinical stage biotechnology company developing its innovative EyeCET platform to enable sustained intraocular production of therapeutic proteins to treat ophthalmic diseases.
Eyevensys’ EyeCET gene therapy technology uses electrotransfection to deliver protein coding plasmids, non-viral, into the ciliary muscle of the eye. This approach facilitates the sustained production of therapeutic proteins, localized within the ciliary muscle cells.
Eyevensys’ lead product EYS606, consists of Eyevensys’ proprietary electro-transfection injection system (ETIS) in combination with plasmid encoding for production of anti-TNFα, for treatment of non-infectious uveitis (NIU). EYS606 is currently in phase I/II clinical trial.
Eyevensys’ vision is to develop a pipeline of therapeutic proteins to address treatment of ophthalmic diseases such as RP, early stage Geographic Atrophy, macular ischemia and other ocular diseases.
GenSight Biologics S.A.
GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Graybug aims to reduce the burden of treatment for patients with vision-threatening diseases through the development of injectable therapeutics that enable less frequent intervention and improve medical delivery for the physician.
LensGen, Inc. is an Irvine, California-based clinical stage company focused on bringing to market Juvene™, a potentially game changing presbyopia-correcting intraocular lens (IOL) for the treatment of cataracts and presbyopia. To date the company has raised $34 million from private and venture investors and is planning a significant Series B Financing in 2019 to complete the PMA study and develop a series of platform IOL products.
Juvene is the world’s first modular fluid optic IOL that uses biomimetic design principals to emulate the natural crystalline lens and provide a continuous range of vision, dynamically from distance to near with high quality optics. By filling the capsule, Juvene offers the promise to resolve many of the current cataract surgery compromises such as IOL shift and rotation, PCO and vitro-retinal tension.
LumiThera, Inc. is a medical device company commercializing a multi-wavelength instrument for the ophthalmologist’s office that improves vision and slows the progression of vision loss in patients with degenerative eye disease. The Company’s focus to date has been on the treatment of patients with dry age-related macular degeneration (AMD). The Company has significant expertise in the use of Photobiomodulation (PBM), which is the use of light therapy to stimulate cells using selected wavelengths. The company received European Union approval to market their Valeda Light Delivery System in 2018. The Valeda demonstrated benefits to patients in the LIGHTSITE I study with its unique multi-wavelength approach. The LIGHTSITE I final results demonstrate improvements in vision, reductions in pathological drusen, and improvements in patient quality of life measures.
An Ophthalmic Home Diagnostic Services company, Notal Vision extends retina disease management from the clinic to the home to improve vision outcomes, reduce patient burden, and address healthcare costs. With a proven approach to the home testing experience, patient-operated devices, and real-time AI-enabled data interpretation, we are advancing eyecare through precision medicine. It is this unique assembly of core competencies that enables us to deliver personalized eyecare to patients. Retinal diseases that present with acute onset, unpredictable activity, and varying drug response pose challenges to healthcare and create addressable unmet needs. Home Diagnostic Services support the promise of enabling patients to retain functional vision throughout their years-long disease journey.
Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology.
With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of eye patients:
NovaTears® improves the signs and symptoms of dry eye disease (DED) and is marketed under CE-approval in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.
Two drugs are in the late stage of clinical development with results expected in Q3 2018:
- CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability, is being evaluated in the pivotal phase 2b/3 ESSENCE trial.
- NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is being evaluated in the phase 2 SEECASE trial.
Headquartered in Heidelberg, Germany, Novaliq has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.
Ocugen is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies to address rare and underserved eye diseases. Ocugen is leveraging its groundbreaking modifier gene therapy platform to address genetically diverse inherited retinal disorders, including its therapies based on the nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410). Ocugen is also developing novel biologic therapies for wet AMD (OCU200)and retinitis pigmentosa (OCU100). Ocugen's late-stage Phase 3 program for patients with ocular graft versus host disease (oGVHD)(OCU300) leverages their patented OcuNanoE - Ocugen's ONE Platform technology to enhance the efficacy of topical ophthalmic therapeutics. OCU300 is the first and only therapeutic with orphan drug designation for oGVHD.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of care by creating sustained release alternatives. It is our intention to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing.
Ocunexus is developing upstream, differentiated technology modulating the inflammasome (NLRP3) by inhibiting pathological overexpression of the Connexin43 (Cx43) hemichannel, a nidus for the assembly of the NLRP3
The company has a Phase 2 ready orally administered small molecule Cx43 inhibitor, with a safety database showing good tolerability and no safety concerns in over 1000 patients, data showing it crosses the blood/brain/retina barrier and an extensive robust preclinical and CMC package for IND submission in ophthalmology. Ocunexus has demonstrated in human cadaver retina that the drug target Cx43, is indeed overexpressed in GA and DR. The company has robust efficacy data both structurally (OCT) and functionally (ERG) in phenotypical models of GA and DR. Plans are to file IND Q4 and be in clinic Q2, 2020.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients bend the cost/time curve of drug development and optimize value in delivering life-changing therapies to improve health.
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop ‘off the shelf’ stem cell treatments, without the need for immunosuppressive drugs. The Company’s lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.
SilkTech Biopharmaceuticals, is a privately held corporation based in the Minneapolis area (Plymouth, MN). The company is devoted to transforming the treatment of Dry Eye Disease (DED) through the use of its patented silk-derived protein-4 (SDP-4) biologic drug candidate, which is produced from the naturally occurring Bombyx mori silkworm cocoon. SDP-4 is a novel biotherapeutic designed to treat DED through a dual-mechanism of action, by physically improving tear film stability and reducing inflammation. SDP-4’s inherent protein nature enhances spreading and wetting properties of aqueous formulations on the ocular surface, emulating the inherent properties of the natural precorneal mucin. In addition, SDP-4 inhibits activation of the NF-κB canonical inflammatory pathway, which is a known contributor to DED symptomatology.
TearClear is developing six glaucoma drugs that meet a critical unmet need for the patient while providing an unmatched safety profile in a manner that no other ophthalmology company has been able to accomplish. TearClear’s platform is comprised of preserved multi-dose pharmaceuticals where the preservative stays in the bottle, but never enters the eye because it is captured at the point of instillation. With demonstrated efficacy in lowering IOP and potential to reduce adverse events, TearClear offers patients the best of both worlds; safely-preserved multi-dose drugs in the bottle, but preservative-free in the eye. Physicians prefer preservative-free therapies. Patients, particularly those who rely on daily drops, prefer multi-use bottles over single-dose units. TearClear is responding to both interests; offering patients the potential for improved outcomes.
Trial Runners is a global, niche ophthalmology CRO shaping the future of clinical trials to help others see the world. Founded in 2006, Trial Runners has worked as a partner on over 70 trials and helped over 10,000 patients on the mission to help improve the quality of life of those suffering from ophthalmology-related conditions around the globe. With offices in North Dakota, Texas, Switzerland, and Australia, Trial Runners is ready and able to work on any ophthalmology trial, anywhere in the world.
Utilizing customized strategies, Trial Runners is able to help the pharmaceutical community by providing unique value, innovation, and expertise. Our differentiator is our exceptional team of experts, ready to help our biotechnology and pharmaceutical partners bring their life-improving drugs, devices, and therapies to market.
Bryn Mawr Communications
Bryn Mawr Communications’ (BMC) eye care publications are uniquely positioned in ophthalmology to serve both physicians’ and industry’s needs.
Cataract & Refractive Surgery Today, Cataract & Refractive Surgery Today Europe, Glaucoma Today, Retina Today, MillennialEYE, and CollaborativeEYE showcase in-depth coverage of surgical approaches, device development, pharmacologic innovations, industry trends, and practice management.
By partnering with key opinion leaders, BMC’s eye care publications balance institutional wisdom with fresh perspectives through print magazines, an expansive video library, and timely news feeds. BMC’s in-house production team brings information directly to physicians through live meetings, simulcasted symposia, live surgeries, and more.
EyeNet is the official news magazine of the American Academy of Ophthalmology and the premier source among the ophthalmic trade press of credible information for ophthalmologists. EyeNet delivers practical clinical information that can be applied immediately in patient care, plus coverage of a broad range of subjects of interest to ophthalmologists, including business and news — all in a concise, highly readable format. For the 9th year in a row, EyeNet is ranked #1 in High Readers, or the most dedicated readers in the field.
Healio.com, the online home of Ocular Surgery News, offers daily news updates, online-only content, extensive CME and specialized email News Wires. Download the new Healio.com/Ocular Surgery News App on iTunes- Search “Ocular Surgery News.” As the best-read newspaper for ophthalmologists, Ocular Surgery News holds a unique place among the eye care publications. With the largest dedicated staff focused solely on ophthalmology, OSN strives to bring our readers a deeper understanding of the news and events that affect their profession.
Media MICE Pte Ltd was founded in 2009 as a medical publishing and innovative content marketing company based in Singapore, serving both Asia-Pacific and international markets. Media MICE specializes in ophthalmology writing, editing, ophthalmic video creation, databases, publications, content marketing, high-tech communication including virtual reality (VR) and augmented reality (AR), event services, and ophthalmic media creation. The company’s relationships with ophthalmic societies, industry, and ophthalmologists make it the go-to firm for connecting and communicating with these important groups in Asia-Pacific and beyond. Contact director Matt Young at email@example.com for more information. PIE Magazine and CAKE Magazine are all operated by Media MICE Pte Ltd.
Three key characteristics set The Ophthalmologist apart:
First, we tell stories. We’re able to tell some of the greatest stories in ophthalmology – straight from the people leading the work, in order to educate, inform, influence and entertain.
Second, we provide genuine insight. The team gets it. The Editorial team all have an academic biomedical research background, have written the papers and stood at the podium. We speak “doctor”, we “do” research.
Third, we engage with everyone. Insight comes from observation and conversation. We travel the world to meet and hear what ophthalmologists, entrepreneurs, key industry figures and policymakers have to say – and that’s directly reflected in the content.
touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content.
The US Ophthalmic Review is a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting.
Ophthalmology Times is a physician-driven media brand that presents cutting-edge advancements and analysis from around the world in surgery, drug therapy, technology, and clinical diagnosis to elevate the delivery of progressive eye health from physician to patient. Ophthalmology Times’ vision is to be the leading content resource for ophthalmologists. Through its multifaceted content channels, Ophthalmology Times will assist physicians with the tools and knowledge necessary to provide advanced quality patient care in the global world of medicine.
Review of Ophthalmology
Review of Ophthalmology is a monthly publication featuring clinically relevant information on surgical technique, new technologies and disease diagnosis and management. Review presents timely articles on ophthalmic subspecialties, such as glaucoma, retina, refractive/cataract surgery, cornea and external disease, pediatric ophthalmology and ocuplastics, as well as current reports on news, regulatory issues, practice management, contact lenses and optical.
The mission of Ethis, Inc., is to facilitate global innovation in eyecare by providing strategic analysis, exceptional content across a wide range of media, and an extensive network of key ophthalmic and optometric opinion leaders to our industry and academic partners around the world.
Glaucoma Research Foundation (GRF) is a national nonprofit founded in 1978 in San Francisco to encourage innovative research toward better treatments for people with glaucoma. GRF has funded more than $50 million of grants and projects in 35 years. In addition to advancing innovation in glaucoma research, GRF provides education and support for people with glaucoma and sponsors catalyst meetings like the annual Glaucoma 360 New Horizons Forum to foster collaboration and speed the cure. The Glaucoma Research Foundation mission is to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.
Market Scope is the leading source for market data, independent perspective, and objective analysis in today’s ophthalmic marketplace.
Market Scope surveys ophthalmologists regarding procedure volumes, surgical techniques, and product use. This data, along with an extensive database, wide-ranging knowledge of ophthalmic products and technology, and comprehensive network of industry contacts, is used to create more than 20 specialized, yearly reports on the ophthalmic industry.
These reports are used to measure performance, make investment decisions, and allocate resources and serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return on investment decisions in the industry. Market Scope has been committed to ophthalmology for more than 20 years and continues to be the most highly valued source for accurate and timely information about ophthalmic markets.
Advancing Diversity in Leadership. OWL is a 900+ member professional organization focused on leadership development. Our mission is to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care. We hold local "OWL Connect" events, online learning sessions and Signature Events at ASCRS and AAO.
Women in Ophthalmology (WIO) is the premiere organization for women ophthalmologists aimed at promoting the personal and professional development of women. WIO serves to educate and provide networking opportunities for women ophthalmologists to sharpen their skills and move forward to change the demographics of leadership in ophthalmology. WIO has become an international organization with formal and informal chapters in multiple states and countries. WIO sponsors panels and functions at meetings throughout the world and the Summer Symposium this past summer had nearly 400 attendees from 6 different countries.